ERBB2 and breast carcinoma: NCT00078572 showed that the median time to disease progression was 27.1 weeks on the combination of lapatinib and capecitabine vs. 18.6 weeks on capecitabine alone in women with advanced or metastatic HER2+ breast cancer whose disease had progressed following treatment with trastuzumab and other cancer therapies (Table 4) [204].